K-Stemcell’s Arthritis Cell Therapy Set For Phase III In Korea
This article was originally published in PharmAsia News
In another positive sign for South Korea’s stem cell space, one of the government’s priorities in the biotech sector, K-Stemcell will begin late-stage clinical trials with JOINTSTEM, an autologus adipose-derived stem cell therapy for degenerative arthritis, with a goal of commercialization in 2018.
You may also be interested in...
A novel stem cell therapy for osteoarthritis developed by South Korean biotech Nature Cell is set to debut in the country this year, providing an alternative for advanced patients who have limited treatment options.
Faced with the risk of losing their investment from a possible stock delisting amid prosecutors’ probes into company’s management, SillaJen’s individual minority shareholders are demanding the Korea Exchange resume trading of the biotech’s stock, in a rare united move.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.